Migraine Drugs Market

SKU: DMMD2530 | Last Updated On: Oct 21 2022 | Available Formats

> Migraine Drugs Market Expected to reach a high CAGR of 15.1% By 2029:

Migraine Drugs Market is segmented By Type (Abortive Medicine, Preventive Medicine), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Migraine Drugs Market

Migraine Drugs Market size was valued USD 2,982.72 million in 2021 and is estimated to reach USD 5,853.46 million by 2029, growing at a CAGR of 15.1% during the forecast period (2022-2029). Migraine is a condition of neurology that can cause multiple symptoms. Severe and debilitating headaches often mark it. Symptoms can include nausea, vomiting, difficulty speaking, numbness or tingling, and others. Migraines occur inside families and influence all ages. Diagnosis of migraine headaches is assessed from clinical history and reported symptoms. Migraines may arise in infancy or may not appear until early adulthood. Females are more prone to experience migraines than men. Genetic background is one of the most common sign factors for migraines. Symptoms of migraines will start one to two days before the headache itself. This is classified as a stage of the prodrome. Migraine pain more often impacts the area of the forehead. It's normally on one side of the head, but on both sides, it may occur.

As per DataM Intelligence, Migraine Drugs Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Migraine Drugs Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Migraine Drugs Market in the United States and Canada produces the utmost share. Whereas the European Migraine Drugs Market is projected to continue its presence globally during the period of 2022- 2029.

Migraine Drugs Market Scope

Metrics

Details

Market CAGR

15.1%

Segments Covered

By Type, By Route of Administration, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Diagnostic Imaging Market, get our Sample Brochure

Market Dynamics

The global migraine drugs market is growing due to several factors such as rising demand for Migraine Drugs due to the increasing prevalence of migraine and headaches, various new cost-effective product launches and novel technological advances.

Rising incidence of migraine and various new technological advancements are expected to drive market growth.

Migraine is perhaps the most common cause of disability in neurology. There has been a substantial increase in migraine cases in recent years. For instance, in Sep 2022, According to Migraine Research Foundation migraine affects over 39 million Americans and women are 3 times more prone to get migraine than men. Epidemiological studies have shown that almost 4.5 percent of Western Europe's population has a headache on at least 15 days a month. As per the study, migraine is the third most common disease and perhaps even the second leading cause of disability worldwide. Thus, a surge in migraine medications is expected to be a key factor in market growth. The growing use of unhealthy products and the increasing prevalence of chronic disease are the main factors responsible for the rise of the demand for migraine drugs.

New technological advancements in market will drive the market growth. For instance, in Jan 2019, Dr. Reddy’s Laboratories and Promius pharma announced the approval of TOSYMRA nasal spray for treatment of migraine with aura or without aura.

Side effects associated with these migraine drugs is expected to hamper the market growth.

Side effects associated with migraine drugs may act as restrain for market growth. However, there is a growing demand in emerging markets due to rising disposal income. Increasing numbers of migraine patients are expected to present a wide range of growth opportunities for market players.

Industry Analysis

The global migraine drugs market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Type segment is expected to hold the largest market share in global migraine drugs market

Global migraine drugs are segmented into type, route of administration, and distribution channel. Based on the type, the market is segmented into preventive and abortive. Based on the route of administration, the market is segmented into injectable, oral, and others. The global migraine drug market is diversified as hospital pharmacies, retail pharmacies, and others based on the distribution channel.

Currently, there are three novel drugs in the late-stage pipeline that are set to change the treatment landscape. These drugs follow disease-modifying approaches and are associated with superior clinical efficacy and a favorable safety profile compared to currently marketed drugs.

Allergan’s ubrogepant and Eli Lilly’s Lasmiditan are expected to be first-in-class migraine drugs with a novel mechanism of action for patients unresponsive to triptans or those who are at risk of cardiovascular disorders. Several triptans under late-stage development consist of reformulating generic triptans to improve the efficacy of existing formulations. Zosano Pharma’s M207 is being investigated in the Phase III ADAM (NCT03282227) trial. The drug is a novel formulation of zolmitriptan delivered via Zosano’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.

Geographical Analysis

North America region holds the largest market share in the global migraine drugs market

By region, the Migraine Drugs market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Migraine Drugs market due to the high usage of migraine drugs. Additionally, Migraine is the third most prevalent and the sixth most disabling illness globally, affecting more than 37 million in the U.S. and over one billion people worldwide. The United States dominated the market with more than 65% share and is projected to maintain its position until 2029. The launch of CGRP based therapies, high prevalence, increasing adoption of novel therapeutics, and a large target population in the U.S. are factors contributing to the country's dominance.

The Asia-Pacific region is expected to have positive market growth due to the growing prevalence of migraine. Furthermore, increasing the adoption of advanced technology to prevent migraine with migraine drugs with the surge in population will boost the market demand over the forecasted period.

Competitive Landscape

The global migraine drugs market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc. and Johnson & Johnson are the leading market players with significant market share.

Leading multinational players dominate the market and hold substantial market share, thereby presenting tough competition to new entrants. Key players focus on various strategic initiatives such as merger & acquisition, geographical expansion, new product launches, and increasing R&D expenditure to stay competitive. For instance, in 2019, Allergen Company announced a New Drug Application for UBRELVY for the acute treatment of migraines with or without aura in adults. This drug was approved by the Food and Drug Administration (United States). This acquisition will affect the growth of the market in the future.

For instance, in Sep 2021, AbbVie announced approval of QULIPTA (atogepant) by United States Food and Drug Administration, for preventive treatment of migraine. It is the only oral CGRP calcitonin gene related peptide receptor antagonist.

Companies are entering into collaborations, acquisitions, mergers, and licensing for increasing their market penetration. For instance, in May 2020, AbbVie Inc. announced complete acquisition of Allergan Plc.

Global Migraine Drugs Market – Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Depakote: This medicine is used for treatment of seizure disorders and to prevent migraine headaches. It restores the balance of some natural substances i.e., neurotransmitters in brain.

Key Developments: In Aug 2022, Abbott announced the approval of spinal cord stimulation device that provides relief in multiple pain areas and provides more options of treatment for growing pain conditions.  

The global migraine drugs market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

 

Frequently Asked Questions

What is the Projected CAGR value of the Functional Migraine Drugs Market ?

Migraine Drugs Market is expected to grow at a CAGR of 15.1% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Migraine Drugs Market  during 2022-2029.

Which is the fastest growing region in the Migraine Drugs Market ?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Acne Drugs Market

Nasal Drug Delivery Systems Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest